Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's revenue per share for the
six
months ended in . 20 was TND0.00.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T does not have enough years/quarters to calculate the revenue per share for the trailing twelve months (TTM) ended in . 20.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
XTUN:SIPHA's 3-Year Revenue Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.7 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Revenue per Share Related Terms
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Revenue per Share Chart
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Annual Data
Trend
Revenue per Share
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Semi-Annual Data
Revenue per Share
XTUN:SIPHA vs BIEI, PTXTQ, INQD: Revenue per Share Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T PS Ratio vs Drug Manufacturers Industry
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a Revenue per Share of TND as of . 20. Revenue per share equals the per-share value of a company's sales. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Revenue per Share too high?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current Revenue per Share is TND. Overall, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Revenue per Share compare to BIEI and PTXTQ?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's Revenue per Share of TND can be compared against companies in the Drug Manufacturers industry. The industry median Revenue per Share is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.70, based on 905 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current Revenue per Share is TND. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T stock overvalued right now?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a current Revenue per Share of TND. The current Revenue per Share is TND. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA), the current Revenue per Share is TND as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T is a Tunisia-based company mainly engaged in manufacturing and distributing medicines and drugs. The company also has its own research and development process to develop generic drugs. It offers pharmaceutical, dietary, hygiene, and cosmetic products in dry, liquid and pasty forms.
12GF Score
Get the complete analysis for XTUN:SIPHA
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTUN:SIPHA has been successfully added to your 
